-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
The adaptive trial opportunity for biotechs and smaller pharmaceutical companies
Tom Parke
Editorial: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Alzheimers disease clinical trials: past failures and future opportunities
Roy Yaari & Ann Hake
Clinical Trail Perspective: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders
Rupert Bauersachs
Clinical Trail Outcomes: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Attention must be paid: adverse event reporting needs improvement
Samuel J Kessler and Charles L Bennett
Editorial: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation
-
Emerging therapies in the management of hypertensive patients with osteoarthritis
Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Gianpaolo Reboldi , Paolo Verdecchia
Review Article: Clinical Investigation